Skip to main content
SpringerLink
Log in

Is surveillance imaging during DLBCL follow-up worthwhile?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. [18F]-fluorodeoxyglucose positron emission tomography

  2. Research for this study was partly funded by Amgen, Humana, Merck and Pfizer.

Reference

  • Huntington SF, et al. Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal of Clinical Oncology : 30 Mar 2015. Available from: URL: http://doi.org/10.1200/JCO.2014.58.5729

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Is surveillance imaging during DLBCL follow-up worthwhile?. PharmacoEcon Outcomes News 725, 19 (2015). https://doi.org/10.1007/s40274-015-2033-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2033-x

Search

Navigation